Genetic and Environmental Contribution to the Co-Occurrence of Endocrine-Metabolic Disorders and Depression: A Nationwide Swedish Study of Siblings.


Journal

The American journal of psychiatry
ISSN: 1535-7228
Titre abrégé: Am J Psychiatry
Pays: United States
ID NLM: 0370512

Informations de publication

Date de publication:
01 11 2022
Historique:
pubmed: 22 9 2022
medline: 3 11 2022
entrez: 21 9 2022
Statut: ppublish

Résumé

Depression is common in individuals with endocrine-metabolic disorders and vice versa, and a better understanding of the underlying factors contributing to the comorbidity of these disorders is needed. This study investigated the familial coaggregation of depression and endocrine-metabolic disorders and estimated the contribution of genetic and environmental factors to their co-occurrence. This population-based cohort study included 2.2 million individuals born in Sweden between 1973 and 1996, with follow-up through 2013. Participants were linked to their biological parents, allowing identification of full siblings, maternal half siblings, and paternal half siblings. Diagnoses of depression and endocrine-metabolic conditions were investigated, with the latter grouped into autoimmune disorders (autoimmune hypothyroidism, Graves' disease, and type 1 diabetes) and non-autoimmune disorders (type 2 diabetes, obesity, and polycystic ovary syndrome). Logistic regression and Cox regression were used to estimate the associations between endocrine-metabolic disorders and depression within the same individual and across siblings. Quantitative genetic modeling was performed to investigate the relative contribution of genetic and environmental influences. Individuals with endocrine-metabolic disorders had a significantly higher risk of depression, with odds ratios ranging from 1.43 (95% CI=1.30, 1.57) for Graves' disease to 3.48 (95% CI=3.25, 3.72) for type 2 diabetes. Increased risks extended to full and half siblings. These correlations were mainly explained by shared genetic influences for non-autoimmune conditions, and by nonshared environmental factors for autoimmune disorders, especially for type 1 diabetes. These findings provide phenotypic and etiological insights into the co-occurrence of depression and various endocrine-metabolic conditions, which could guide future research aiming at identifying pathophysiological mechanisms and intervention targets.

Identifiants

pubmed: 36128682
doi: 10.1176/appi.ajp.21090954
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

824-832

Commentaires et corrections

Type : CommentIn

Auteurs

Marica Leone (M)

Janssen Pharmaceutical Companies of Johnson & Johnson, Solna, Sweden (Leone, Leval); Department of Medical Epidemiology and Biostatistics (Leone, Kuja-Halkola, Leval, Butwicka, Zhang, Liu, Larsson, Bergen) and Department of Molecular Medicine and Surgery (Skov), Karolinska Institutet, Solna, Sweden; Child and Adolescent Psychiatry Stockholm, Stockholm Health Care Services, Region Stockholm, Sweden (Butwicka); Department of Child Psychiatry, Medical University of Warsaw, Warsaw (Butwicka); Department of Biostatistics and Translational Medicine, Medical University of Lodz, Lodz, Poland (Butwicka); Department of Medicine, Karlstad Central Hospital, Karlstad, Sweden (Skov); School of Medical Sciences, Örebro University, Örebro, Sweden (Larsson).

Ralf Kuja-Halkola (R)

Janssen Pharmaceutical Companies of Johnson & Johnson, Solna, Sweden (Leone, Leval); Department of Medical Epidemiology and Biostatistics (Leone, Kuja-Halkola, Leval, Butwicka, Zhang, Liu, Larsson, Bergen) and Department of Molecular Medicine and Surgery (Skov), Karolinska Institutet, Solna, Sweden; Child and Adolescent Psychiatry Stockholm, Stockholm Health Care Services, Region Stockholm, Sweden (Butwicka); Department of Child Psychiatry, Medical University of Warsaw, Warsaw (Butwicka); Department of Biostatistics and Translational Medicine, Medical University of Lodz, Lodz, Poland (Butwicka); Department of Medicine, Karlstad Central Hospital, Karlstad, Sweden (Skov); School of Medical Sciences, Örebro University, Örebro, Sweden (Larsson).

Amy Leval (A)

Janssen Pharmaceutical Companies of Johnson & Johnson, Solna, Sweden (Leone, Leval); Department of Medical Epidemiology and Biostatistics (Leone, Kuja-Halkola, Leval, Butwicka, Zhang, Liu, Larsson, Bergen) and Department of Molecular Medicine and Surgery (Skov), Karolinska Institutet, Solna, Sweden; Child and Adolescent Psychiatry Stockholm, Stockholm Health Care Services, Region Stockholm, Sweden (Butwicka); Department of Child Psychiatry, Medical University of Warsaw, Warsaw (Butwicka); Department of Biostatistics and Translational Medicine, Medical University of Lodz, Lodz, Poland (Butwicka); Department of Medicine, Karlstad Central Hospital, Karlstad, Sweden (Skov); School of Medical Sciences, Örebro University, Örebro, Sweden (Larsson).

Agnieszka Butwicka (A)

Janssen Pharmaceutical Companies of Johnson & Johnson, Solna, Sweden (Leone, Leval); Department of Medical Epidemiology and Biostatistics (Leone, Kuja-Halkola, Leval, Butwicka, Zhang, Liu, Larsson, Bergen) and Department of Molecular Medicine and Surgery (Skov), Karolinska Institutet, Solna, Sweden; Child and Adolescent Psychiatry Stockholm, Stockholm Health Care Services, Region Stockholm, Sweden (Butwicka); Department of Child Psychiatry, Medical University of Warsaw, Warsaw (Butwicka); Department of Biostatistics and Translational Medicine, Medical University of Lodz, Lodz, Poland (Butwicka); Department of Medicine, Karlstad Central Hospital, Karlstad, Sweden (Skov); School of Medical Sciences, Örebro University, Örebro, Sweden (Larsson).

Jakob Skov (J)

Janssen Pharmaceutical Companies of Johnson & Johnson, Solna, Sweden (Leone, Leval); Department of Medical Epidemiology and Biostatistics (Leone, Kuja-Halkola, Leval, Butwicka, Zhang, Liu, Larsson, Bergen) and Department of Molecular Medicine and Surgery (Skov), Karolinska Institutet, Solna, Sweden; Child and Adolescent Psychiatry Stockholm, Stockholm Health Care Services, Region Stockholm, Sweden (Butwicka); Department of Child Psychiatry, Medical University of Warsaw, Warsaw (Butwicka); Department of Biostatistics and Translational Medicine, Medical University of Lodz, Lodz, Poland (Butwicka); Department of Medicine, Karlstad Central Hospital, Karlstad, Sweden (Skov); School of Medical Sciences, Örebro University, Örebro, Sweden (Larsson).

Ruyue Zhang (R)

Janssen Pharmaceutical Companies of Johnson & Johnson, Solna, Sweden (Leone, Leval); Department of Medical Epidemiology and Biostatistics (Leone, Kuja-Halkola, Leval, Butwicka, Zhang, Liu, Larsson, Bergen) and Department of Molecular Medicine and Surgery (Skov), Karolinska Institutet, Solna, Sweden; Child and Adolescent Psychiatry Stockholm, Stockholm Health Care Services, Region Stockholm, Sweden (Butwicka); Department of Child Psychiatry, Medical University of Warsaw, Warsaw (Butwicka); Department of Biostatistics and Translational Medicine, Medical University of Lodz, Lodz, Poland (Butwicka); Department of Medicine, Karlstad Central Hospital, Karlstad, Sweden (Skov); School of Medical Sciences, Örebro University, Örebro, Sweden (Larsson).

Shengxin Liu (S)

Janssen Pharmaceutical Companies of Johnson & Johnson, Solna, Sweden (Leone, Leval); Department of Medical Epidemiology and Biostatistics (Leone, Kuja-Halkola, Leval, Butwicka, Zhang, Liu, Larsson, Bergen) and Department of Molecular Medicine and Surgery (Skov), Karolinska Institutet, Solna, Sweden; Child and Adolescent Psychiatry Stockholm, Stockholm Health Care Services, Region Stockholm, Sweden (Butwicka); Department of Child Psychiatry, Medical University of Warsaw, Warsaw (Butwicka); Department of Biostatistics and Translational Medicine, Medical University of Lodz, Lodz, Poland (Butwicka); Department of Medicine, Karlstad Central Hospital, Karlstad, Sweden (Skov); School of Medical Sciences, Örebro University, Örebro, Sweden (Larsson).

Henrik Larsson (H)

Janssen Pharmaceutical Companies of Johnson & Johnson, Solna, Sweden (Leone, Leval); Department of Medical Epidemiology and Biostatistics (Leone, Kuja-Halkola, Leval, Butwicka, Zhang, Liu, Larsson, Bergen) and Department of Molecular Medicine and Surgery (Skov), Karolinska Institutet, Solna, Sweden; Child and Adolescent Psychiatry Stockholm, Stockholm Health Care Services, Region Stockholm, Sweden (Butwicka); Department of Child Psychiatry, Medical University of Warsaw, Warsaw (Butwicka); Department of Biostatistics and Translational Medicine, Medical University of Lodz, Lodz, Poland (Butwicka); Department of Medicine, Karlstad Central Hospital, Karlstad, Sweden (Skov); School of Medical Sciences, Örebro University, Örebro, Sweden (Larsson).

Sarah E Bergen (SE)

Janssen Pharmaceutical Companies of Johnson & Johnson, Solna, Sweden (Leone, Leval); Department of Medical Epidemiology and Biostatistics (Leone, Kuja-Halkola, Leval, Butwicka, Zhang, Liu, Larsson, Bergen) and Department of Molecular Medicine and Surgery (Skov), Karolinska Institutet, Solna, Sweden; Child and Adolescent Psychiatry Stockholm, Stockholm Health Care Services, Region Stockholm, Sweden (Butwicka); Department of Child Psychiatry, Medical University of Warsaw, Warsaw (Butwicka); Department of Biostatistics and Translational Medicine, Medical University of Lodz, Lodz, Poland (Butwicka); Department of Medicine, Karlstad Central Hospital, Karlstad, Sweden (Skov); School of Medical Sciences, Örebro University, Örebro, Sweden (Larsson).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH